N/A N=92 Healing Lodge First Face Training Evaluation Study
Addiction · Depression/Anxiety · Trauma, Psychological
Primary: Attitudes Towards Serious Mental Illness - Adolescent Version — 2.05; 1.94; 1.96 Score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=71 Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
Primary: Percentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE) — 13; 15; 15; 12 Participants
Phase 3 N=73 Full-Time Occlusion Therapy for Intermittent Exotropia in Children
Intermittent Exotropia
Primary: Number of Participants With a Change in Mean Distance Control Scores at 3 Months — 1; 0; 4; 4 Participants
Phase 2 N=963 RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
Long COVID · Long Covid19
Primary: Total Number of Participants Enrolled in Each Appendix — 323; 320; 320 Participants
N/A N=8 Achieving Nutritional Adequacy Of Vitamin E With An Egg/Plant-Based Food Pairing
Nutritional Requirements
Primary: Vitamin E Area Under the Curve (0-72 h) — 2.90; 5.24; 5.18; 4.39 umol/L*h
N/A N=241 Tertulias Social Isolation Women's Groups Study
Social Isolation · Depression
Primary: Change in Depression — -2.01; -5.10 units on a scale — p=0.0473
Phase 2 N=456 The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
Systemic Lupus Erythematosus
Primary: Cohort A: Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-A (CLASI-A) Total Score at Week 16 — -5.0; -9.0; -10.2; -9.7 scores on a…
N/A N=451 Group-based Mindfulness for Chronic Pain in the Primary Care Setting
Chronic Pain · Back Pain
Primary: Pain Intensity and Interference at Baseline, 8 Weeks, 6 Months (Primary Timepoint), & 12 Months: Pain, Enjoyment, General Activity (PEG) Score — 6.37; 5.87; 5.21; 5.6…
Phase 1 N=64 A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 1270.92; 1320.24…
N/A N=27 Wrist Cooling for Hot Flashes Clinical Trial
Hot Flashes
Primary: Number and Severity of Hot Flashes — 1148; 692; 924; 1213 number of hot flashes
Phase 2 N=162 Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
Stroke · Rhabdomyolysis · Jaundice
Primary: Total Number of Participants With an Increase in Liver Function Tests (LFTs) — 1; 2 Participants
Phase 3 N=628 A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause
Vasomotor Symptoms Associated With Menopause · Hot Flashes
Primary: Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD]) — 6.71; 6.81; -5.40; -3.50 Number of…
Phase 2 N=59 Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
Osteosarcoma · Ewing Sarcoma · Rhabdomyosarcoma
Primary: Response Rate — 15.3 percentage of participants
Phase 1 N=12 A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) — 2070; 3740 hours*nanomoles/Liter…
Phase 1 N=15 A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 75.1; 69.3 Hours * nanomol…